Sun Pharma to Settle US Generics Pricing Case for $200 Million

Sun Pharmaceutical Industries Ltd. settled claims worth $200 million in an antitrust case in Pennsylvania alleging that the firm, along with others, colluded to fix prices of generic drugs.

The units of India’s number one drugmaker — Sun Pharmaceutical Industries Inc. and Taro Pharmaceuticals USA Inc. — will pay the suing consumers in exchange for a full release of all claims against them, the company said in a statement to Indian exchanges Thursday.

The amounts may be reduced if “more than a certain percentage of the total insured class members opt out of the putative class,” the company said, adding ...